Kornimate/medical-research-clean huggingface dataset:
evaluation of the efficacy and safety of a hyaluronic acid gel in adhesion prevention after open thyroidectomy.

Conditions: Adhesion; Thyroid Diseases

Summary: the aim of this study is to assess the safety and efficacy of hanbio barrigel to prevent thyroidectomy postoperative adhesions

the objective of this study is to evaluate the efficacy of hanbio barrigel in the prevention of postoperative adhesion for patients who will undergo open thyroidectomy. the dysphagia and adhesion severity will be assessed at specific visits pre and/or post-operation for both treatment group and control group. the post-operative condition, and the adverse event information will be collected for evaluation of tolerability and safety of the product.

Eligibility criteria:
inclusion criteria: * male and female between 20 and 70 years of age. * patients diagnosed with benign goiter or thyroid cancer that will undergo open thyroidectomy (either unilateral or bilateral total thyroidectomy with or without central lymph node dissection). * naïve patients to thyroid surgery. * subjects are willing to comply with all aspects of the study and have signed informed consent form. exclusion criteria: * pregnant or lactating female patients. * presence of severe and uncontrolled illness such as stroke, hypertension, diabetes, chronic renal failure, coagulopathy, drug abuse. * patients with previous neck radiotherapy within 1 year. * concurrent diseases/conditions which will be unable to evaluate the outcomes. * patients receiving any adhesion prevention adjuvant. * previous history of keloid or hypertrophic scar. * anticoagulant used within a week from surgery. * subjects are hypersensitive to sodium hyaluronate. * participate in another clinical trial within 1 month. * patients presence of surgical site infection. * patients are with abnormal clinical test (appendix 1) result within one month or ecog performance status (appendix 2) score ranged from 3-4.
a study of adverse events and suspected adverse drug reactions in patients under apixaban for prevention of stroke and systemic embolism with non-valvular atrial fibrillation and venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery

Conditions: Cerebral Stroke; Thrombosis, Deep Vein; Pulmonary Embolism

Summary: to characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with apixaban, according to therapeutic indications approved in mexico.


Eligibility criteria:
inclusion criteria: * a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. * patients (men and women) over 18 years old. * patients who have received at least one dose of apixaban for prevention of stroke and systemic embolism with non-valvular atrial fibrillation with one or more of the following stroke risk factors: prior stoke or transient ischaemic attack; age \>75; hypertension; diabetes mellitus; symptomatic heart failure (nyha class \>ii); or for prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. * subjects who are willing and able to comply with all scheduled visits. exclusion criteria: * patients who have received apixaban in a clinical trial. * patients who received apixaban for another indication locally approved or have a contraindication according to the information to prescribe of the product in mexico. * hypersensitivity to the active substance or to any of the excipients. * active clinically significant bleeding. * hepatic disease associated with coagulopathy and clinically relevant bleeding risk. * lesion or condition considered a significant risk factor for major bleeding. this may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. * concomitant treatment with any other anticoagulant agent e.g. unfractionated heparin (ufh), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), and oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except under specific circumstances of switching anticoagulant therapy. concomitant medication with nonsteroidal anti-inflammatory drugs (nsaids ). * pregnancy and breast-feeding. * severe acute or chronic psychiatric condition and other significant medical condition.
mediterranean vs. high-fermented-food diet adherence on inflammation in lupus

Conditions: Lupus Erythematosus, Systemic

Summary: this is a 4-month randomized controlled trial to evaluate the feasibility of 'good and very good' adherence to the mediterranean dietary pattern and to a high-fermented-food diet by individuals with systemic lupus erythematosus (sle).

given the demonstrated beneficial effects of the mediterranean dietary pattern in autoimmune disease and the potential benefit of a high-fermented-food diet on inflammatory profiles, we aim to determine the feasibility and relative benefit of a mediterranean dietary pattern versus a high-fermented-food diet on inflammatory markers and clinical outcomes in individuals with sle. the primary aim of the study is to evaluate the feasibility of 'good and very good' adherence to the mediterranean dietary pattern and to a high-fermented-food diet by individuals with sle. secondary aims will determine the effects of the mediterranean dietary pattern and a high-fermented-food diet on attenuating inflammation and disease activity in individuals with sle. this is a 4-month randomized controlled trial with a 1-month baseline of usual diet and 3-month intervention. participants will complete the online dhq iii and diet adherence questionnaires monthly. blood will be obtained at randomization and at the end of the intervention period for analysis of inflammatory cytokines. dietary intake during baseline and intervention will be assessed by 5, asa 24-h dietary recalls.

Eligibility criteria:
inclusion criteria: * \> 18 years of age * able to provide informed consent and undertake study questionnaire completion in english * meets sle diagnostic criteria and is currently under the care of a rheumatologist, nephrologist, or other physician regarding sle care * be willing and able to comply with all the study-related procedures exclusion criteria: * pregnant or planning pregnancy within the duration of the interventional study. * currently following a vegetarian/vegan diet. * allergy/sensitivity to gluten, soy, or cow's milk. * self-disclosure of lactose intolerance * inability to comply with the study procedures. * baseline dietary fiber intake \> 30 g/day * medas score at baseline \> 9 * baseline consumption of \> 2 servings per day of fermented foods

Keywords: sle lupus mediterranean diet fermented food inflammation
can the different instruments used ın root canal treatment have an effect on postoperative pain?

Conditions: Postoperative Pain

Summary: root canal treatment is a treatment method in which the pulp is irreversibly infected due to caries or trauma or when the pulp loses its vitality. biomechanical preparation of primary teeth is an important step for a successful root canal treatment. the success of root canal treatment depends not only on the biological results of the treatment, but also on minimizing the postoperative pain of the patients. therefore, the elimination of factors associated with postoperative pain has an important role in the prognosis of patients after treatment. in all root canal preparation methods, some debris overflows from the apical. debris protruding into the apical area causes postoperative pain. many studies in the literature have shown that niti rotary files cause less extrusion of debris compared to hand files, and therefore less postoperative pain. within the scope of this study, the effect of niti k hand file and waveone gold, protaper next, endoart niti pedo gold file, af baby rotary file systems on postoperative pain in root canal treatment preparations applied to the mandibular primary molar teeth of pediatric patients aged 5-8 years. it is intended to be evaluated using vas). in our research; protaper next (ptn), waveone gold (wog), af baby rotary file, endoart niti pedo gold file, niti k type hand files were used. 100 patients between the ages of 5 and 8 who had root canal treatment indications for mandibular primary second molars were included in the study. the patients were divided into 5 groups with 20 patients in each group. all systems were used according to the manufacturer's instructions and all treatments were performed by a single operator in a single session. postoperative pain was recorded using the visual analog scale (vas) at the 6th, 12th, 18th, 24th, 48th, 72nd hour and 1st week following treatment. the obtained data were evaluated statistically.


Eligibility criteria:
inclusion criteria: * no analgesic use 12 hours before root canal treatment * no systemic disease. * teeth with a diagnosis of irreversible pulpitis, no other teeth causing pain at the site of the tooth to be treated, no inter-root bone loss exceeding 1/3, and root canal inclinations of no more than 25° according to schneider method were included in the study. exclusion criteria: * patients with post-procedural analgesic use were excluded from the study * patients whose parents did not fully understand the instructions and who did not attend the follow-up visit one week after treatment were excluded.

Keywords: root canal treatment nickel-titanium instruments postoperative pain primary tooth
effect of transcranial static magnetic field stimulation in fibromyalgia syndrome

Conditions: Fibromyalgia

Summary: the main objective is to know if the transcranial static magnetic field stimulation (tsms) reduces the perception of pain in patients with fibromyalgia and its effect on health-related quality of life. in addition, it will seek to limit the parameters necessary to achieve efficiency with the technique.

background: various non-invasive brain stimulation techniques have been successfully tested in fibromyalgia syndrome (fms). transcranial static magnetic field stimulation (tsms) is a new, portable and inexpensive non invasive brain stimulation (nibs) technique that has shown security, biological effects, and therapeutical effects in some pathologies. some studies have studied its effect in pain central processing, our aim is to study its effect on fms. the safety that tsms has demonstrated in several clinical trials opens doors to future clinical trials that will extend its clinical utility. objectives: to investigate the effect of tsms on pain in patients with fms, using subjective and objective assessment measures. identify dose response to the treatment to limit the parameters required to achieve effectiveness with the technique.

Eligibility criteria:
inclusion criteria: * formal diagnosis of fibromyalgia syndrome (fms). * no change in the last 4 weeks on their standard treatment. * they must have pain for more than 6 months (at least 4 on the vas scale). * score on the fibromyalgia impact questionnaire (fiq) greater than 39. exclusion criteria: * presence of concomitant autoimmune or hematologic diseases. * neuropsychiatric disorders. * pacemakers or neurostimulators implants. * substance abuse or other pathologies that can explain chronic pain. * pregnant or lactating women. * those who are receiving any other type of physiotherapy treatment.

Keywords: transcranial static magnetic field stimulation fibromyalgia pain
risk factors for acute kidney injury in critically ill patients with acute-on-chronic liver failure

Conditions: Acute Kidney Injury; Acute-On-Chronic Liver Failure

Summary: acute kidney injury (aki) is one of the most important factors associated with increased mortality in patients with acute-on-chronic liver failure (aoclf). early identification and treatment of this subgroup of patients may improve survival and decrease icu length of stay. as kidney ischemia is one of the main mechanisms responsible for aki in aoclf, an increase in urinary to arterial partial pressure of oxygen may help in the early diagnosis of renal failure. for this arterial and urinary oxygen pressure will be measured at icu admission, on day 1 and day 3 of icu stay. diagnosis of aki within the first 28 days after icu admission will be recorded


Eligibility criteria:
inclusion criteria: - patients admitted to the icu for acute-on-chronic liver failure exclusion criteria: * pre-existing renal disease * urine output\<200 ml/day * death within the first 24 hours after icu admission * emergency liver transplantation within the follow-up period (28 days)
coaxial drainage versus standard chest tube after pulmonary lobectomy

Conditions: Lung Cancer

Summary: objectives: chest tubes are routinely inserted after thoracic surgery procedures in different size and numbers. the aim of this study is to assess the efficacy of smart drain coaxial drainage compared with two standard chest tubes in patients undergoing thoracotomy for pulmonary lobectomy. 98 patients (57 males and 41 females, mean age 68.3±7.4 years) with lung cancer undergoing open pulmonary lobectomy were randomized in two groups: 50 received one upper 28-fr and one lower 32-fr standard chest tube (st group) and 48 received one 28-fr smart drain coaxial tube (ct group). hospitalization data, quantity of fluid output, air leaks, radiograph findings, pain control and costs were assessed.


Eligibility criteria:
inclusion criteria: * age more than 18 years * patients scheduled for pulmonary lobectomy exclusion criteria: * middle lobectomy, * extended resections, minimally invasive lobectomies, * previous ipsilateral thoracic surgery, * induction chemo and/or radiotherapy * patients who did not give consent to participate.
primary hyperoxaluria mutation genotyping

Conditions: Primary Hyperoxaluria

Summary: this study will help us determine whether certain genetic mutations, more than others, are a cause of more severe disease in primary hyperoxaluria.

during your study visit, we will draw one tube, about two teaspoonfuls (1 to 1 ½ teaspoons for children), of blood from your arm to obtain white blood cells. these white blood cells will be used as a source of dna for genetic testing. we will use the isolated dna to try to identify the gene that is defective in primary hyperoxaluria by comparing it with the structure of genes in normal individuals, patients with primary hyperoxaluria, and family members of primary hyperoxaluria patients. in family members of primary hyperoxaluria patients, a 24 hour urine test may also be collected.

Eligibility criteria:
inclusion criteria: * you have been diagnosed, or you are in the process of being diagnosed primary hyperoxaluria * you have a family member diagnosed with primary hyperoxaluria

Keywords: ph ph type i primary hyperoxaluria hyperoxaluria primary oxalosis ph type ii ph type iii genetic testing for ph genetic testing for primary hyperoxaluria hereditary study for ph hereditary study for primary hyperoxaluria
impact of a rehabilitation programme for mothers with breast cancer and their children

Conditions: Breast Cancer

Summary: about 1/3 of newly diagnosed breast cancer patients are mothers of children who still live at home. they face additional challenges and stress, their children are also affected by the mother's illness. the oncological rehabilitation programme "getting better together" focuses on these special family needs. this waiting-control-group study examines the effectiveness of the intervention by accompanying the patients and their children over the course of a year and assessing their quality of life and psychological health.

about 1/3 of newly diagnosed breast cancer patients are mothers of children who still live at home. they face additional challenges and stress, their children are also affected by the mother's illness. the oncological rehabilitation programme "getting better together", administered by the rexrodt von fircks foundation and the clinic ostseedeich in groemitz, germany, focuses on these special family needs. this waiting-control-group-study, designed and executed at the philipps university marburg medical center, department of child and adolescent psychiatry, examines the effectiveness of the intervention by accompanying the patients and their children over the course of a year and assessing their quality of life and psychological health. the primary outcome measure for mothers is the health related quality of life as assessed by the eortc qlq-c30 and br-23; children's adaptation is assessed with the ilk (inventory for the assessment of quality of life of children and adolescents) as well as the strengths and difficulties questionnaire (sdq)

Eligibility criteria:
inclusion criteria: * participants of the rehabilitation programme "getting better together" * mothers of children up to the age of 16 * have been diagnosed with and treated for breast cancer for the first time in their lives * chemotherapy or radiation therapy ended no less than 6 weeks ago exclusion criteria: * metastases

Keywords: breast cancer quality of life children of somatically ill parents psychological adaptation
prediction of emergency department admission volume

Conditions: Emergency

Summary: retrospective cohort. schedule emergency service overload periods on different terms, by hour or time slot over several days.


Eligibility criteria:
minor patients refusal of inclusion in a study explicitly stated in the medical record objection to the use of data or refusal to participate no consultation at the emergency department in the year prior to the study
does low-does cervical epidural lidocaine cause transient weakness?

Conditions: Cervical Radiculopathy

Summary: "does low-does cervical epidural lidocaine cause transient weakness?"

cervical radicular pain is relatively common, often treated with epidural steroid injection (esi), when conservative treatments like oral analgesics, physical therapy, and activity modification have failed. there are no universal clinical practice guidelines for the use of diluents when cesi are performed. interlaminar cesi may be performed with or without the use of local anesthetics, due to training bias or theoretical concerns of weakness. cesi without the benefit of local anesthetic as a steroid diluent increases the latency of pain relief and may decrease diagnostic information immediately after a cesi with regard to pain generators responsible for symptoms, and may potentially decrease patient satisfaction. by evaluating the effects of local anesthetic as a diluent during interlaminar cervical esi, we will enhance the safety of this treatment with regard to expectations of objective motor weakness as well as post procedure pain control in the recovery phase after the injection procedure. additionally, investigation of short-term pain, function, medication use, and global impression of change following use of local anesthetic versus saline as a diluent during interlaminar cervical esi will provide evidence to inform the optimization of clinical outcomes related to steroid diluent choice.

Eligibility criteria:
inclusion criteria: 1. age 18-80. 2. clinical diagnosis of cervical radicular pain. 3. magnetic resonance imaging pathology consistent with clinical symptoms/signs. 4. numerical rating scale (nrs) pain score of 4 or higher. 5. pain duration of more than 6 weeks despite trial of conservative therapy (medications, physical therapy, or chiropractic care). 6. patients who will undergo cesi for treatment of cervical radiculitis. exclusion criteria: 1. refusal to participate, provide consent, or provide communication and follow-up information for duration of the study. 2. inability to perform handgrip or arm strength testing. 3. contraindications to cervical esi (active infection, bleeding disorders, current anticoagulant or antiplatelet medication use, allergy to medications used for ciesi, and pregnancy). 4. current glucocorticoid use or esi within past 6 months. 5. prior cervical spine surgery. 6. cervical spinal cord lesions; cerebrovascular, demyelinating, or other neuro-muscular muscular disease. 7. patient request for or requirement of conscious sedation for the injection procedure.

Keywords: cervical epidural steroid injection local anesthetic upper extremity weakness
liposomal doxorubicin and trastuzumab in treating women with advanced breast cancer

Conditions: Breast Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing. monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. purpose: phase i/ii trial to study the effectiveness of liposomal doxorubicin and trastuzumab in treating women who have advanced breast cancer.

objectives: * determine the toxicity, including cardiac toxicity, of doxorubicin hcl liposome and trastuzumab (herceptin) in women with advanced her-2/neu-overexpressing breast cancer. * determine the efficacy of this regimen in these patients. outline: patients receive doxorubicin hcl liposome iv over 1 hour on day 1, followed by trastuzumab (herceptin) iv over 30-90 minutes on days 1, 8, and 15. courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months. projected accrual: a total of 40 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically proven breast cancer * metastatic disease or * locoregional relapse following optimal adjuvant therapy and regional treatment * her-2/neu overexpression (3+ by immunohistochemistry or gene amplification by fish) * hormone receptor status: * not specified patient characteristics: age: * 18 and over sex: * female menopausal status: * not specified performance status: * ecog 0-2 life expectancy: * not specified hematopoietic: * absolute neutrophil count at least 1,500/mm3 * platelet count at least 100,000/mm3 * hemoglobin at least 10 g/dl hepatic: * sgot and sgpt no greater than 3 times upper limit of normal (uln) * alkaline phosphatase no greater than 2 times uln unless documented to be arising from bone * bilirubin no greater than 1.5 times uln renal: * bun less than 1.5 times uln * creatinine less than 1.5 times uln cardiovascular: * lvef normal by radioisotope method * no history of congestive cardiac failure, myocardial infarction, cardiac arrhythmia, or ischemic heart disease requiring medication other: * not pregnant or nursing * fertile patients must use effective contraception * no known sensitivity to benzyl alcohol * no other prior malignancy except adequately treated nonmelanomatous skin cancer or carcinoma in situ of the cervix prior concurrent therapy: * see disease characteristics biologic therapy: * not specified chemotherapy: * no prior doxorubicin greater than 240 mg/m2 endocrine therapy: * not specified radiotherapy: * prior radiotherapy to left breast or chest wall allowed surgery: * not specified

Keywords: stage iv breast cancer recurrent breast cancer